Sovereign Financial Group Inc. decreased its position in iShares Biotechnology ETF (NASDAQ:IBB – Free Report) by 1.8% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 5,711 shares of the financial services provider’s stock after selling 105 shares during the period. Sovereign Financial Group Inc.’s holdings in iShares Biotechnology ETF were worth $832,000 at the end of the most recent quarter.
Other institutional investors have also bought and sold shares of the company. BNP Paribas Financial Markets increased its stake in shares of iShares Biotechnology ETF by 25.7% in the 1st quarter. BNP Paribas Financial Markets now owns 2,055,373 shares of the financial services provider’s stock valued at $282,038,000 after acquiring an additional 420,053 shares in the last quarter. Main Management ETF Advisors LLC grew its stake in shares of iShares Biotechnology ETF by 2.6% in the 2nd quarter. Main Management ETF Advisors LLC now owns 578,835 shares of the financial services provider’s stock valued at $79,451,000 after buying an additional 14,535 shares during the period. Global Assets Advisory LLC bought a new stake in iShares Biotechnology ETF in the 1st quarter valued at about $66,059,000. Raymond James Financial Services Advisors Inc. raised its stake in iShares Biotechnology ETF by 24.6% during the 2nd quarter. Raymond James Financial Services Advisors Inc. now owns 217,047 shares of the financial services provider’s stock worth $29,792,000 after buying an additional 42,822 shares during the period. Finally, Commonwealth Equity Services LLC boosted its holdings in iShares Biotechnology ETF by 5.3% in the first quarter. Commonwealth Equity Services LLC now owns 198,709 shares of the financial services provider’s stock worth $27,267,000 after acquiring an additional 10,033 shares in the last quarter. Institutional investors own 62.45% of the company’s stock.
iShares Biotechnology ETF Price Performance
NASDAQ IBB opened at $143.00 on Wednesday. The company has a fifty day simple moving average of $145.27 and a 200 day simple moving average of $139.22. iShares Biotechnology ETF has a 12-month low of $111.83 and a 12-month high of $150.57.
iShares Biotechnology ETF Announces Dividend
iShares Biotechnology ETF Company Profile
iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.
Read More
- Five stocks we like better than iShares Biotechnology ETF
- Business Services Stocks Investing
- Don’t Sleep on Skye Bioscience—This Weight Loss Drug Could Soar
- How to Evaluate a Stock Before Buying
- Pinterest: Time to Jump Onboard for Long-Term Gains?
- What Are Dividend Contenders? Investing in Dividend Contenders
- 4 Best ETFs for Capitalizing on the Semiconductor Market Surge
Receive News & Ratings for iShares Biotechnology ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iShares Biotechnology ETF and related companies with MarketBeat.com's FREE daily email newsletter.